Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Derazantinib (ARQ-087) 是一种有效的,ATP 竞争型的,具有口服活性的酪氨酸激酶抑制剂,能够抑制软骨细胞FGFR1 (IC50:4.5 nM)、FGFR2 (IC50:1.8 nM)、FGFR3 (IC50:4.35nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 656 | 现货 | ||
2 mg | ¥ 955 | 现货 | ||
5 mg | ¥ 1,570 | 现货 | ||
10 mg | ¥ 2,890 | 现货 | ||
25 mg | ¥ 4,850 | 现货 | ||
50 mg | ¥ 6,890 | 现货 | ||
100 mg | ¥ 9,330 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,630 | 现货 |
产品描述 | Derazantinib (ARQ-087) (ARQ-087) is an ATP competitive tyrosine kinase inhibitor. It exhibits potent activity against FGFR1/FGFR2/FGFR3 chondrocytes (IC50s: 4.5 nM/1.8 nM/4.5 nM). |
靶点活性 | FGFR3:4.5 nM, FGFR1:4.5 nM, FGFR2:1.8 nM |
体外活性 | 在细胞中,通过对Derazantinib的响应,明显可以看到FGFR2自磷酸化及FGFR途径下游其它蛋白质(FRS2α, AKT, ERK)的抑制。Derazantinib对于因FGFR失调(包括扩增、融合和突变)而增殖的细胞系具有抗增殖作用。在高水平表达FGFR2蛋白的细胞系的细胞周期研究中,Derazantinib诱导的G1期细胞周期阻滞与后续的凋亡诱导之间存在正相关[1]。Derazantinib能够在EC50约为100 nM时,解救FGF2介导的生长停滞,且在高达500 nM的浓度下没有显著毒性。在70-500 nM的浓度范围内,Derazantinib显著抑制FGF2的效应。Derazantinib抑制FGF介导的细胞外基质丧失与软骨细胞过早衰老的诱导,并在胫骨培养中解救FGF介导的软骨细胞分化抑制。在无细胞激酶试验中,Derazantinib抑制FGFR1-4但不抑制其他受体酪氨酸激酶。Derazantinib还能抑制与颅缝早闭症相关的FGFR1和FGFR2突变[2]。 |
体内活性 | Derazantinib在含有FGFR2基因扩增和融合的SNU-16及NCI-H716异种移植瘤模型中有效抑制肿瘤生长[1]。在Derazantinib注射的翼部,大多数胚胎展现出异常的外部表型(81.3%),这可能是由于抑制了肢芽间充质的增殖[2]。 |
激酶实验 | Derazantinib is titrated in DMSO utilizing a 3-fold dilution scheme and then diluted 10-fold further in deionized water for a final DMSO concentration of 10%. A volume (2.5 μL) of these dilutions or vehicle is added to each well of a reaction plate. FGFR1 or FGFR2 is added to assay buffer to each well in a volume of 17.5 μL for a final concentration of 0.50 or 0.25 nM, respectively. After a 30-minute pre-incubation period, ATP and substrate are added in assay buffer (5 μL) for final concentrations of 0-1,000 μM ATP and 80 nM biotinylated-PYK2, for a final reaction volume of 25 μL. The plates are incubated for 60 minutes at room temperature and then stopped in the dark by the addition of 10 μL stop/detection mixture prepared in assay buffer containing EDTA [1]. |
细胞实验 | Cells are seeded at 3000-5000 cells per well with 130 μL media in 96-well tissue culture-treated plates. The cells are incubated overnight and subsequently treated with 3-fold serial dilutions of Derazantinib starting at 100 μM. The cells are returned to a 37°C humidified incubator for 72 hours. Cell proliferation is measured using the MTS assay [1]. |
动物实验 | Female NCr nu/nu mice (SNU-16) or CB17 SCID mice (NCI-H716) with well established (400 mg) subcutaneous tumors are given a single oral dose of Derazantinib or vehicle control. Plasma and tumor samples are collected 4 hours post single dose. Derazantinib is administered orally. The dosing volume for all groups is 10 mL/kg or 0.1 mL/10 g body weight [1]. |
别名 | ARQ-087 |
分子量 | 468.57 |
分子式 | C29H29FN4O |
CAS No. | 1234356-69-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 98 mg/mL (209.15 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1342 mL | 10.6708 mL | 21.3415 mL | 53.3538 mL |
5 mM | 0.4268 mL | 2.1342 mL | 4.2683 mL | 10.6708 mL | |
10 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL | 5.3354 mL | |
20 mM | 0.1067 mL | 0.5335 mL | 1.0671 mL | 2.6677 mL | |
50 mM | 0.0427 mL | 0.2134 mL | 0.4268 mL | 1.0671 mL | |
100 mM | 0.0213 mL | 0.1067 mL | 0.2134 mL | 0.5335 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Derazantinib 1234356-69-4 Angiogenesis Tyrosine Kinase/Adaptors FGFR ARQ-087 ARQ087 Fibroblast growth factor receptor inhibit ARQ 087 Inhibitor inhibitor